1ACC/ESC EXPERT CONSENSUS DOCUMENT. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol, 2003,42:1687-1713; European Heart Journal, 2003,24:1965-1991.
2AHA Scientific Statement. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation, 2004,109:2807-2816.
3Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force3 on the Definition and Classification of Cardiomyopathies. Circulation, 1996,93:841-842.
4Maron BJ. Hypertrophic cardiomyopathy in childhood. Pediatr Clin N Am, 2004,51:1305-1346.
6Hughes SE, McKenna WJ. New insight into the pathology of inherited cardiomyopathy. Heart, 2005,91:257-264.
7Doolan A,Tebo M,Semsarian C, et al. Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences. J Mol Cell Cardiol, 2005,38: 387-393.
10Camm AJ. Should we afford implantable cardioverter defibrillator therapy. Nature Clinical Practice Cardiovascular Medicine, 2005,2:59.
二级参考文献15
1Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo, the Cardiac Arrhythmia Suppression Trial. N Engl J Med,1991, 324:781-788.
2Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med, 1996, 335:1933-1940.
3Ezekowitz JA, Armstrong PW, Mc Alister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med ,2003, 138:445-452.
4Buxton AE, Lee KL, Fisher KD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med, 1999, 341:1882-1890.
5Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease; an analysis of patients enrolled in Multicenter Unsustained Tachycardia Trial. Circulation,
6Moss AJ. Dead is dead, but can we identify patients at increased risk for sudden cardiac death? J Am Coll Cardiol,2003, 42:659-660.
7Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol ,2003, 14:S87-S95.
8Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? an analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol, 2003, 42:81-87.
9Gregoratos G, Abrams J, Epstein AE,et al. ACC/ AHA/ NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices (ACC/ AHA/ NASPE Committee to Update the 1998 Pacemaker Guidelines) .Circulation, 2002, 106: 2145-2161.
10Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med, 2002, 346:877-883.
